Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma
Introduction. Glioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12–15 months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic strategies. We used NanoString GeoMx® Digital Spatial Profi...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2021, Vol.2021, p.8819702-9, Article 8819702 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | |
| container_start_page | 8819702 |
| container_title | Journal of oncology |
| container_volume | 2021 |
| creator | Barber, H. Tofias, A. Lander, B. Daniels, A. Gong, J. Ren, Y. Ren, X. Liang, Y. White, P. Kurian, K. M. |
| description | Introduction. Glioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12–15 months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic strategies. We used NanoString GeoMx® Digital Spatial Profiling (DSP) to assess multiple immunooncology protein targets in methylated versus unmethylated IDH-wild-type glioblastoma. Methods. NanoString GeoMx® DSP technology uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROIs) are selected with bound fluorescent antibodies; oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immunooncology proteins and controls (CD4, CD14, CD68, CD8A, B7-H3, PD-L1, CD19, FOXP3, CD44, STAT3 (phospho Y705), CD45, Pan Cytokeratin, MS4A1/CD20, CD45RO, PD1, CD3, beta-2 microglobulin, VISTA, Bcl2, GZMB, PTEN, beta-catenin, CD56, Ki-67, STAT3, AKT, p-Akt, S6, Histone H3, IgG Rabbit control, and Mouse IgG control) from ROIs in a cohort of 10 IDH-wild-type glioblastomas (5 methylated and 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using technical and biological replicates. Results. The analysis showed 10/27 immunooncology target proteins were significantly increased in methylated versus unmethylated IDH-wild-type glioblastoma tumour core (false discovery rate (FDR) |
| doi_str_mv | 10.1155/2021/8819702 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1155_2021_8819702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A684360200</galeid><sourcerecordid>A684360200</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-b3e37f0a08935191991bdcdfb5f0717bbf3429f39eefb46ef3fa3fada19715053</originalsourceid><addsrcrecordid>eNqNklGL1DAQx4so3nn65rMUfBF0vaRp2uZFWHp6t3CHgrv4GNI0aXOkyV6S3rJ-Jb-kKbvunj4cQmCGzG_-kwz_JHkNwUcIMT7PQAbPqwqSEmRPklNYVOWsyjF4-iA_SV54fwtAkQNSPE9OECIE44ycJr_m7T0zXLTpjdWCj5q5tO6ZYzwIp36yoKxJV16ZLr1QnQpMp9_X8TbGb85KpafKUvDeWG27bRrpxTCMxlrDdzdL5joRfKpMeiNCv9UsxGm1HdbMxWSjQp-uzHAsLS6uZj-UbsN2LdJLrWyjmQ92YC-TZ5JpL17t41my-vJ5WV_Nrr9eLur59YxjkIdZgwQqJWCgIghDAgmBTctb2WAJSlg2jUR5RiQiQsgmL4REksXTsrhCiAFGZ8mnne56bAbRcmGCY5qunRqY21LLFP27YlRPO3tPq7hdXE4C7_YCzt6Nwgc6KM-F1swIO3qa4azKUYYrFNG3_6C3dnQmfm-icpDhqHmkOqYFVUbaOJdPonRekIKAMs_x41QcWIAMgEh92FHcWe-dkIePQUAnR9HJUXTvqIi_ebiMA_zHQhGodsBGNFZ6rkS00wED0XRFTlCGYgZgHR00Waq2owmx9f3_tx7pXpmWbdTj7_4NlFz2ZA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2524025096</pqid></control><display><type>article</type><title>Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma</title><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Barber, H. ; Tofias, A. ; Lander, B. ; Daniels, A. ; Gong, J. ; Ren, Y. ; Ren, X. ; Liang, Y. ; White, P. ; Kurian, K. M.</creator><contributor>Qian, Liren ; Liren Qian</contributor><creatorcontrib>Barber, H. ; Tofias, A. ; Lander, B. ; Daniels, A. ; Gong, J. ; Ren, Y. ; Ren, X. ; Liang, Y. ; White, P. ; Kurian, K. M. ; Qian, Liren ; Liren Qian</creatorcontrib><description>Introduction. Glioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12–15 months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic strategies. We used NanoString GeoMx® Digital Spatial Profiling (DSP) to assess multiple immunooncology protein targets in methylated versus unmethylated IDH-wild-type glioblastoma. Methods. NanoString GeoMx® DSP technology uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROIs) are selected with bound fluorescent antibodies; oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immunooncology proteins and controls (CD4, CD14, CD68, CD8A, B7-H3, PD-L1, CD19, FOXP3, CD44, STAT3 (phospho Y705), CD45, Pan Cytokeratin, MS4A1/CD20, CD45RO, PD1, CD3, beta-2 microglobulin, VISTA, Bcl2, GZMB, PTEN, beta-catenin, CD56, Ki-67, STAT3, AKT, p-Akt, S6, Histone H3, IgG Rabbit control, and Mouse IgG control) from ROIs in a cohort of 10 IDH-wild-type glioblastomas (5 methylated and 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using technical and biological replicates. Results. The analysis showed 10/27 immunooncology target proteins were significantly increased in methylated versus unmethylated IDH-wild-type glioblastoma tumour core (false discovery rate (FDR) <0.1 by Benjamini–Hochberg procedure). Conclusions. NanoString GeoMx® DSP was used to analyse multiple immunooncology protein target expression in methylated versus unmethylated IDH-wild-type glioblastoma. In this small study, there was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein expression in methylated versus unmethylated GBM tumour core; however, this requires larger cohort validation. Advanced multiplex immunooncological biomarker analysis may be useful in identifying biomarkers for novel immunotherapeutic agents in GBMs.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>EISSN: 1687-8469</identifier><identifier>DOI: 10.1155/2021/8819702</identifier><identifier>PMID: 33995529</identifier><language>eng</language><publisher>LONDON: Hindawi</publisher><subject>Antibodies ; Automation ; Brain cancer ; Brain tumors ; Comparative analysis ; Digital signal processors ; Gene expression ; Glioblastoma multiforme ; Immunotherapy ; Life Sciences & Biomedicine ; Medical prognosis ; Oncology ; Proteins ; Science & Technology ; Technology application ; Viral antibodies</subject><ispartof>Journal of oncology, 2021, Vol.2021, p.8819702-9, Article 8819702</ispartof><rights>Copyright © 2021 H. Barber et al.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>Copyright © 2021 H. Barber et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 H. Barber et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>8</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000664932300001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c504t-b3e37f0a08935191991bdcdfb5f0717bbf3429f39eefb46ef3fa3fada19715053</citedby><cites>FETCH-LOGICAL-c504t-b3e37f0a08935191991bdcdfb5f0717bbf3429f39eefb46ef3fa3fada19715053</cites><orcidid>0000-0002-5047-3856 ; 0000-0001-6794-3036 ; 0000-0002-7503-9896 ; 0000-0003-0303-3716 ; 0000-0002-5457-3686 ; 0000-0001-5173-9022 ; 0000-0002-6457-4340 ; 0000-0002-6619-1001</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096575/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096575/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,4025,27927,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33995529$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Qian, Liren</contributor><contributor>Liren Qian</contributor><creatorcontrib>Barber, H.</creatorcontrib><creatorcontrib>Tofias, A.</creatorcontrib><creatorcontrib>Lander, B.</creatorcontrib><creatorcontrib>Daniels, A.</creatorcontrib><creatorcontrib>Gong, J.</creatorcontrib><creatorcontrib>Ren, Y.</creatorcontrib><creatorcontrib>Ren, X.</creatorcontrib><creatorcontrib>Liang, Y.</creatorcontrib><creatorcontrib>White, P.</creatorcontrib><creatorcontrib>Kurian, K. M.</creatorcontrib><title>Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma</title><title>Journal of oncology</title><addtitle>J ONCOL</addtitle><addtitle>J Oncol</addtitle><description>Introduction. Glioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12–15 months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic strategies. We used NanoString GeoMx® Digital Spatial Profiling (DSP) to assess multiple immunooncology protein targets in methylated versus unmethylated IDH-wild-type glioblastoma. Methods. NanoString GeoMx® DSP technology uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROIs) are selected with bound fluorescent antibodies; oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immunooncology proteins and controls (CD4, CD14, CD68, CD8A, B7-H3, PD-L1, CD19, FOXP3, CD44, STAT3 (phospho Y705), CD45, Pan Cytokeratin, MS4A1/CD20, CD45RO, PD1, CD3, beta-2 microglobulin, VISTA, Bcl2, GZMB, PTEN, beta-catenin, CD56, Ki-67, STAT3, AKT, p-Akt, S6, Histone H3, IgG Rabbit control, and Mouse IgG control) from ROIs in a cohort of 10 IDH-wild-type glioblastomas (5 methylated and 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using technical and biological replicates. Results. The analysis showed 10/27 immunooncology target proteins were significantly increased in methylated versus unmethylated IDH-wild-type glioblastoma tumour core (false discovery rate (FDR) <0.1 by Benjamini–Hochberg procedure). Conclusions. NanoString GeoMx® DSP was used to analyse multiple immunooncology protein target expression in methylated versus unmethylated IDH-wild-type glioblastoma. In this small study, there was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein expression in methylated versus unmethylated GBM tumour core; however, this requires larger cohort validation. Advanced multiplex immunooncological biomarker analysis may be useful in identifying biomarkers for novel immunotherapeutic agents in GBMs.</description><subject>Antibodies</subject><subject>Automation</subject><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>Comparative analysis</subject><subject>Digital signal processors</subject><subject>Gene expression</subject><subject>Glioblastoma multiforme</subject><subject>Immunotherapy</subject><subject>Life Sciences & Biomedicine</subject><subject>Medical prognosis</subject><subject>Oncology</subject><subject>Proteins</subject><subject>Science & Technology</subject><subject>Technology application</subject><subject>Viral antibodies</subject><issn>1687-8450</issn><issn>1687-8450</issn><issn>1687-8469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNklGL1DAQx4so3nn65rMUfBF0vaRp2uZFWHp6t3CHgrv4GNI0aXOkyV6S3rJ-Jb-kKbvunj4cQmCGzG_-kwz_JHkNwUcIMT7PQAbPqwqSEmRPklNYVOWsyjF4-iA_SV54fwtAkQNSPE9OECIE44ycJr_m7T0zXLTpjdWCj5q5tO6ZYzwIp36yoKxJV16ZLr1QnQpMp9_X8TbGb85KpafKUvDeWG27bRrpxTCMxlrDdzdL5joRfKpMeiNCv9UsxGm1HdbMxWSjQp-uzHAsLS6uZj-UbsN2LdJLrWyjmQ92YC-TZ5JpL17t41my-vJ5WV_Nrr9eLur59YxjkIdZgwQqJWCgIghDAgmBTctb2WAJSlg2jUR5RiQiQsgmL4REksXTsrhCiAFGZ8mnne56bAbRcmGCY5qunRqY21LLFP27YlRPO3tPq7hdXE4C7_YCzt6Nwgc6KM-F1swIO3qa4azKUYYrFNG3_6C3dnQmfm-icpDhqHmkOqYFVUbaOJdPonRekIKAMs_x41QcWIAMgEh92FHcWe-dkIePQUAnR9HJUXTvqIi_ebiMA_zHQhGodsBGNFZ6rkS00wED0XRFTlCGYgZgHR00Waq2owmx9f3_tx7pXpmWbdTj7_4NlFz2ZA</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Barber, H.</creator><creator>Tofias, A.</creator><creator>Lander, B.</creator><creator>Daniels, A.</creator><creator>Gong, J.</creator><creator>Ren, Y.</creator><creator>Ren, X.</creator><creator>Liang, Y.</creator><creator>White, P.</creator><creator>Kurian, K. M.</creator><general>Hindawi</general><general>Hindawi Publishing Group</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5047-3856</orcidid><orcidid>https://orcid.org/0000-0001-6794-3036</orcidid><orcidid>https://orcid.org/0000-0002-7503-9896</orcidid><orcidid>https://orcid.org/0000-0003-0303-3716</orcidid><orcidid>https://orcid.org/0000-0002-5457-3686</orcidid><orcidid>https://orcid.org/0000-0001-5173-9022</orcidid><orcidid>https://orcid.org/0000-0002-6457-4340</orcidid><orcidid>https://orcid.org/0000-0002-6619-1001</orcidid></search><sort><creationdate>2021</creationdate><title>Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma</title><author>Barber, H. ; Tofias, A. ; Lander, B. ; Daniels, A. ; Gong, J. ; Ren, Y. ; Ren, X. ; Liang, Y. ; White, P. ; Kurian, K. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-b3e37f0a08935191991bdcdfb5f0717bbf3429f39eefb46ef3fa3fada19715053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Automation</topic><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>Comparative analysis</topic><topic>Digital signal processors</topic><topic>Gene expression</topic><topic>Glioblastoma multiforme</topic><topic>Immunotherapy</topic><topic>Life Sciences & Biomedicine</topic><topic>Medical prognosis</topic><topic>Oncology</topic><topic>Proteins</topic><topic>Science & Technology</topic><topic>Technology application</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barber, H.</creatorcontrib><creatorcontrib>Tofias, A.</creatorcontrib><creatorcontrib>Lander, B.</creatorcontrib><creatorcontrib>Daniels, A.</creatorcontrib><creatorcontrib>Gong, J.</creatorcontrib><creatorcontrib>Ren, Y.</creatorcontrib><creatorcontrib>Ren, X.</creatorcontrib><creatorcontrib>Liang, Y.</creatorcontrib><creatorcontrib>White, P.</creatorcontrib><creatorcontrib>Kurian, K. M.</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Proquest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barber, H.</au><au>Tofias, A.</au><au>Lander, B.</au><au>Daniels, A.</au><au>Gong, J.</au><au>Ren, Y.</au><au>Ren, X.</au><au>Liang, Y.</au><au>White, P.</au><au>Kurian, K. M.</au><au>Qian, Liren</au><au>Liren Qian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma</atitle><jtitle>Journal of oncology</jtitle><stitle>J ONCOL</stitle><addtitle>J Oncol</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>8819702</spage><epage>9</epage><pages>8819702-9</pages><artnum>8819702</artnum><issn>1687-8450</issn><eissn>1687-8450</eissn><eissn>1687-8469</eissn><abstract>Introduction. Glioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12–15 months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic strategies. We used NanoString GeoMx® Digital Spatial Profiling (DSP) to assess multiple immunooncology protein targets in methylated versus unmethylated IDH-wild-type glioblastoma. Methods. NanoString GeoMx® DSP technology uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROIs) are selected with bound fluorescent antibodies; oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immunooncology proteins and controls (CD4, CD14, CD68, CD8A, B7-H3, PD-L1, CD19, FOXP3, CD44, STAT3 (phospho Y705), CD45, Pan Cytokeratin, MS4A1/CD20, CD45RO, PD1, CD3, beta-2 microglobulin, VISTA, Bcl2, GZMB, PTEN, beta-catenin, CD56, Ki-67, STAT3, AKT, p-Akt, S6, Histone H3, IgG Rabbit control, and Mouse IgG control) from ROIs in a cohort of 10 IDH-wild-type glioblastomas (5 methylated and 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using technical and biological replicates. Results. The analysis showed 10/27 immunooncology target proteins were significantly increased in methylated versus unmethylated IDH-wild-type glioblastoma tumour core (false discovery rate (FDR) <0.1 by Benjamini–Hochberg procedure). Conclusions. NanoString GeoMx® DSP was used to analyse multiple immunooncology protein target expression in methylated versus unmethylated IDH-wild-type glioblastoma. In this small study, there was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein expression in methylated versus unmethylated GBM tumour core; however, this requires larger cohort validation. Advanced multiplex immunooncological biomarker analysis may be useful in identifying biomarkers for novel immunotherapeutic agents in GBMs.</abstract><cop>LONDON</cop><pub>Hindawi</pub><pmid>33995529</pmid><doi>10.1155/2021/8819702</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-5047-3856</orcidid><orcidid>https://orcid.org/0000-0001-6794-3036</orcidid><orcidid>https://orcid.org/0000-0002-7503-9896</orcidid><orcidid>https://orcid.org/0000-0003-0303-3716</orcidid><orcidid>https://orcid.org/0000-0002-5457-3686</orcidid><orcidid>https://orcid.org/0000-0001-5173-9022</orcidid><orcidid>https://orcid.org/0000-0002-6457-4340</orcidid><orcidid>https://orcid.org/0000-0002-6619-1001</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2021, Vol.2021, p.8819702-9, Article 8819702 |
| issn | 1687-8450 1687-8450 1687-8469 |
| language | eng |
| recordid | cdi_crossref_primary_10_1155_2021_8819702 |
| source | PubMed Central Open Access; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antibodies Automation Brain cancer Brain tumors Comparative analysis Digital signal processors Gene expression Glioblastoma multiforme Immunotherapy Life Sciences & Biomedicine Medical prognosis Oncology Proteins Science & Technology Technology application Viral antibodies |
| title | Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T04%3A37%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advanced%20Molecular%20Characterization%20Using%20Digital%20Spatial%20Profiling%20Technology%20on%20Immunooncology%20Targets%20in%20Methylated%20Compared%20with%20Unmethylated%20IDH-Wildtype%20Glioblastoma&rft.jtitle=Journal%20of%20oncology&rft.au=Barber,%20H.&rft.date=2021&rft.volume=2021&rft.spage=8819702&rft.epage=9&rft.pages=8819702-9&rft.artnum=8819702&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2021/8819702&rft_dat=%3Cgale_cross%3EA684360200%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2524025096&rft_id=info:pmid/33995529&rft_galeid=A684360200&rfr_iscdi=true |